On April 4, Hong Kong stocks’ anti epidemic concept stocks rose collectively. As of the closing, Kaifa pharmaceutical-b rose nearly 37%, Geli pharmaceutical-b and Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) etc. rose more than 10%, and stone Pharmaceutical Group and Cansino Biologics Inc(688185) biology-b all rose more than 5%.
In terms of news, since April 3, the domestic covid-19 virus vaccine of China biopharmaceutical and Cansino Biologics Inc(688185) biological has been approved by the State Food and drug administration to carry out clinical trials, and the domestic covid-19 virus vaccine of Shijiazhuang Pharmaceutical Group has been approved by the State Food and drug administration to carry out clinical studies.
three companies have made progress in covid-19 vaccine research and development
In April 3rd, the official account of China’s biological official published the article that the two generation of recombinant COVID-19 vaccine of China biological group was approved by the State Administration of pharmaceutical products. The vaccine was independently developed by the Chinese Academy of biology, with good safety and tolerance. It can stimulate the human body to produce high-level neutralizing antibodies against prototype strains and major mutant strains. In the clinical trials used for sequential reinforcement, it showed good effects on variants such as Omicron. The vaccine was approved for emergency use in the UAE at the end of December 2021, becoming the first second-generation covid-19 vaccine approved for emergency use in the world.
On the same day, Shijiazhuang Pharmaceutical Group announced that its independently developed covid-19 virus mRNA vaccine sys6006 has been approved by the State Food and Drug Administration and can carry out clinical research in China. The vaccine has good long-term immune protection against the current mainstream mutant strains including Omicron and delta, with good safety and stability, and can meet the demand of large-scale production capacity supply.
Cansino Biologics Inc(688185) bio announced on the morning of April 4 that the covid-19 virus mRNA vaccine developed by the group has been approved by the drug clinical trial of the State Food and drug administration. Preclinical research results show that the vaccine can induce high titer neutralizing antibodies against a variety of important variants identified by the World Health Organization (including current epidemic strains), which can more effectively protect the body from the infection of existing variants.
domestic covid-19 vaccine research and development accelerated
Zheng Zhongwei, director of the science and technology development center of the National Health Commission, introduced that the research and development of covid-19 vaccine in China has always been in the first place in the world, and has now realized the full coverage of clinical trials of five technical routes. As of March 2022, 6 inactivated vaccines, 12 recombinant protein vaccines, 5 adenovirus vector vaccines and 5 mRNA and DNA vaccines (nucleic acid vaccines) have entered the clinical stage, and many of them are undergoing overseas phase III clinical trials. Adenovirus vector inhalation vaccine and attenuated influenza virus vector nasal spray vaccine are currently undergoing phase III clinical trials abroad.
Specifically, Walvax Biotechnology Co.Ltd(300142) and Aibo biology have jointly developed covid-19 mRNA vaccine, which has obtained phase III clinical trial approval in many countries, and will have an annual production capacity of about 400 million doses; The adenovirus vector covid-19 vaccine jointly developed by AstraZeneca and Shenzhen Kangtai Biological Products Co.Ltd(300601) has obtained the emergency use license of basic immunization and booster needle in Indonesia Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) the nasal spray influenza virus vector covid-19 vaccine developed in cooperation with the University of Hong Kong has entered clinical phase III Livzon Pharmaceutical Group Inc(000513) and the Institute of biophysics of the Chinese Academy of Sciences jointly developed the recombinant covid-19 virus fusion protein vaccine. The phase III interim data showed good protection.
In addition, the research and development of monovalent and multivalent vaccines against Omicron variants has also made rapid progress. The inactivated vaccine has carried out the research and development of Omicron monovalent vaccine, delta + Omicron bivalent vaccine and prototype strain + delta + Omicron trivalent vaccine, and the preclinical research has been basically completed and production verification has been carried out; The recombinant protein vaccine has carried out the research and development of alpha + beta + delta + Omicron tetravalent vaccine, and is applying for overseas clinical trials. In addition, some vaccines previously approved in China are promoting phase III clinical sequential research abroad. Zheng Zhongwei said that the existing vaccination and enhanced needle vaccination are still effective for the Omicron variant.
The policy level also vigorously promoted the research and development of covid-19 vaccine. The “14th five year plan” for the development of pharmaceutical industry points out that it is necessary to accelerate product innovation and technological breakthroughs in industrialization, and focus on the development of new covid-19 virus vaccine, multivalent HPV vaccine and other products in the field of vaccine.
related companies’ performance rose sharply last year
According to the official website data of the National Health Commission, as of April 3, 31 provinces (autonomous regions and municipalities directly under the central government) and Xinjiang production and Construction Corps had reported 3279249 million doses of covid-19 virus vaccine.
Cansino Biologics Inc(688185) , Chongqing Zhifei Biological Products Co.Ltd(300122) , Shenzhen Kangtai Biological Products Co.Ltd(300601) have issued relevant performance announcements in 2021.
Shenzhen Kangtai Biological Products Co.Ltd(300601) expects the net profit attributable to the parent company in 2021 to be 1.2-1.4 billion yuan, with a year-on-year increase of 76.68% – 106.13% Shenzhen Kangtai Biological Products Co.Ltd(300601) said that in the face of the demand for major disease prevention and control, the company responded quickly, promoted the listing and sales of new products in an orderly manner, continuously optimized the layout of marketing network and strengthened market promotion. Product sales increased steadily and the company’s net profit increased significantly compared with the same period last year.
Chongqing Zhifei Biological Products Co.Ltd(300122) 2021 realized a net profit attributable to the parent company of 10.197 billion yuan, with a year-on-year increase of 208.88%. The company attributed the performance growth to “increasing R & D investment, pushing through the old and bringing forth the new, and steadily improving the sales of independent products and agency products” Chongqing Zhifei Biological Products Co.Ltd(300122) revealed in the latest online teleconference that the company focuses on the diagnosis, prevention and treatment of infectious diseases. Zhikeweide, a recombinant covid-19 virus protein vaccine developed in cooperation with the Institute of Microbiology of the Chinese Academy of Sciences, has been approved for registration and listing or emergency use in many international places in China.
Cansino Biologics Inc(688185) 2021 operating revenue increased by 1717482% year on year, reaching 4.3 billion yuan; The net profit attributable to the parent company was 1.914 billion yuan, turning losses into profits, and became the first biotechnology company to “pick u” on the science and innovation board. In this regard, the company said that it was mainly because its recombinant covid-19 virus vaccine (adenovirus type 5 vector) obtained conditional listing approval and emergency use authorization from many countries at home and abroad. The commercialization of the product had a positive impact on the total operating revenue and relevant profit indicators.
Securities companies believe that under the background of normalized prevention and control of covid-19 epidemic, covid-19 vaccine not only brings certain performance increment to relevant enterprises, but also gives enterprises an opportunity period to quickly develop and iterate, accelerate mass production, reserve new technologies, lay out new platforms and overcome difficulties under special circumstances. In the long run, the construction and improvement of domestic mRNA and other emerging vaccine technology platforms are expected to start the next high business cycle of the technology driven industry.
